Abstracts
Showing 852 abstracts.
Citation
Prashan Malhotra, M.D., L. Pompucci, Ph.D., Rahul Jain, Helena Schmidtmayerova, Ph.D. Plasma levels of b-chemokines do not associate with vertical transmission of HIV-1. Presented at: 44th Infectious Diseases Society of America Annual Meeting.Conference
44th Infectious Diseases Society of America Annual Meeting
Citation
Yvonne J.K. Edwards, Margaret McManus, Eric R. Weiss, Eric Mick, Katherine Luzuriaga, PACTG 356 Investigators. Plasma proteomic profiles in HIV-1 infected children with and without viral control. Presented at: CROI 2018.Conference
CROI 2018
Citation
Kumud K. Singh, Michael Hughes, Ph.D., Jie (Ellen) Chen, M.S., Stephen A. Spector, M.D. Polymorphisms in the gene encoding for CX3CR1 are important determinants of HIV-1 related disease progression of children. Presented at: 11th Conference on Retroviruses and Opportunistic Infections.Conference
11th Conference on Retroviruses and Opportunistic Infections
Citation
John Sabo, M.S., Pedro E. Cahn, M.D., Marinella Della Negra, Ph.D., Guido Castelli-Gattinara, Claudia Fortuny, Ram Yogev, M.D., Juan Carlos Salazar, M.D., M.P.H., Chan-Loi Yong, Jaromir Mikl, Ante Jelaska, M.D. Population pharmacokinetic (PK) assessment of systemic steady-state tipranavir (TPV) concentrations for HIV+ pediatric patients administered tipranavir/ritonavir (TPV/r) 290/115 mg/m^2 and 375/150 mg/m^2 BID (BI 1182.14 and PACTG 1051 study team). Presented at: 13th Conference on Retroviruses and Opportunistic Infections.Conference
13th Conference on Retroviruses and Opportunistic Infections
Study
P1051
Citation
M. L. Rizk, L. Du, L. Wenning, C. Bennetto-Hood , E. P. Acosta Merck & Co., Inc. Population Pharmacokinetic Analysis of Raltegravir Pediatric Formulations in HIV-infected Children 4 weeks to 18 years of Age. Presented at: ICAAC 2014.Conference
ICAAC 2014
Study
P1066
Citation
Kensuke Shoji, Brookie M. Best, Mark Mirochnick, Alice Stek, Jiajia Wang, Tim R. Cressey, David Shapiro, Edmund V. Capparelli for IMPAACT P1026s. Population Pharmacokinetic Assessment of Factors Associated with Tenofovir Clearance in Pregnant and Postpartum Women with HIV infection in IMPAACT P1026s. Presented at: ICAAC 2015.Conference
ICAAC 2015
Study
P1026S
Citation
Hardik Chandasana, Sven van Dijkman, Rashmi Mehta, Mark Bush, Helena Rabie, Patricia Flynn, Tim R. Cressey, Edward Acosta, Jennifer Kiser, Kristina M. Brooks. Population Pharmacokinetic Modeling of FDC DTG/ABC/3TC to Support Dosing in Children with HIV-1. Presented at: CROI 2024; 2024 Mar 05.Conference
CROI 2024
Study
IMPAACT 2019
Citation
Population Pharmacokinetics (PK) of Lopinavir During Pregnancy and Postpartum. Presented at: IDSA IDWeek.Conference
IDSA IDWeek
Study
P1026S
Citation
Edmund Capparelli, Pharm.D., James D. Connor, M.D., Janet Ailene Englund, M.D., Carol J. Baker, M.D., Claire Raskino, M.S., Paul Palumbo, M.D., Stephen A. Spector, M.D. Population Pharmacokinetics and Pharmacodynamics Of Dideoxynosine (ddl) In Children With HIV Infection.Citation
Jeremiah D. Momper, Steven Sun, Mina Nikanjam, Mark Mirochnick, Kathleen M. Powis, Alice Stek, Kristina M. Brooks, Brookie M. Best, Edmund V. Capparelli. Population Pharmacokinetics of Bictegravir in Pregnant and Postpartum Persons Living with HIV. Presented at: American College of Clinical Pharmacology.Conference
American College of Clinical Pharmacology
Study
IMPAACT 2026